南财智讯1月26日电，圣达生物公告，公司股东天台万健投资发展中心（有限合伙）因资金规划需要， 拟于2026年2月25日至2026年5月24日期间，通过集中竞价和大宗交易方式减持公司股份不超过567.0888 万股，即不超过公司总股本的3%。其中，集中竞价方式减持不超过189.0296万股（不超过总股本 1%），大宗交易方式减持不超过378.0592万股（不超过总股本2%）。减持价格视市场价格确定。 ...

Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million and 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the previous year, which corresponds to a year-on-year growth of 69.93% to 120.90% [2][3] - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 43 million and 58 million yuan, indicating an increase of 20.5359 million to 35.5359 million yuan, with a year-on-year growth of 91.42% to 158.19% [2][3] Group 2: Previous Year Performance - In the previous year, the total profit was 49.0853 million yuan, with a net profit attributable to shareholders of the parent company at 29.4245 million yuan, and a net profit excluding non-recurring gains and losses at 22.4641 million yuan [5] Group 3: Reasons for Performance Increase - The increase in performance is attributed to the company's continuous promotion of refined management and technological upgrades, which have further optimized operational efficiency and cost structure. Additionally, the company has deepened its differentiated competition strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [5] Group 4: Asset Impairment Provision - The company plans to recognize an asset impairment provision totaling approximately 9.15 million yuan for the year 2025, which includes a credit impairment loss of 0.65 million yuan and an asset impairment loss of 8.5 million yuan related to inventory [9][10] - The total impairment provision is expected to reduce the net profit attributable to shareholders of the listed company by 9.15 million yuan for the year 2025 [11]

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

Core Viewpoint - Shengda Bio (603079) announced on January 22 that it expects a significant increase in net profit for 2025, projecting a range of 50 million to 65 million yuan, representing a year-on-year growth of 69.93% to 120.90% [1] Financial Performance - The company anticipates net profit to be between 50 million yuan and 65 million yuan for the year 2025 [1] - This projection indicates a substantial year-on-year increase in net profit, with growth rates estimated between 69.93% and 120.90% [1]

Group 1 - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million to 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the same period last year, which translates to a year-on-year growth of 69.93% to 120.9% [1] - The main reasons for the performance change include the company's continuous promotion of refined management and technological upgrades, which further optimized operational efficiency and cost structure [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [1]

Core Viewpoint - The company, 圣达生物, expects significant growth in net profit for the year 2025, with projections indicating an increase of 69.93% to 120.90% compared to the previous year [1] Financial Projections - The company anticipates a net profit attributable to shareholders of the parent company to be between 50 million and 65 million yuan for 2025 [1] - The projected net profit, excluding non-recurring gains and losses, is expected to be between 43 million and 58 million yuan, reflecting a year-on-year growth of 91.42% to 158.19% [1] Operational Improvements - The company has enhanced operational efficiency and cost structure through continuous fine management and technological upgrades [1] - A differentiated competitive strategy has been deepened, with increased market expansion efforts to seize market opportunities, contributing to overall profitability improvement [1]

报告期内，公司通过持续推动精细化管理与技术升级，进一步优化了运营效率与成本结构。同时，公司 深化差异化竞争战略，加大市场拓展力度，抓住市场机会，推动了公司整体盈利能力的提升。 圣达生物（603079）(603079.SH)披露2025年年度业绩预增公告，公司预计2025年年度实现归属于母公 司所有者的净利润为5000万元至6500万元，同比增长69.93%至120.90%。预计2025年年度实现归属于母 公司所有者的扣除非经常性损益的净利润为4300万元至5800万元，同比增长91.42%至158.19%。 ...

Core Viewpoint - The company, Shengda Bio (603079.SH), expects a significant increase in net profit for the year 2025, projecting a growth of 69.93% to 120.90% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the owners of the parent company for 2025 is projected to be between 50 million to 65 million yuan [1] - The estimated net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be between 43 million to 58 million yuan, reflecting a growth of 91.42% to 158.19% [1] Operational Strategy - The company has improved operational efficiency and cost structure through continuous fine management and technological upgrades [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts to seize market opportunities, enhancing overall profitability [1]

证券代码：603079 证券简称：圣达生物 公告编号：2026-003 浙江圣达生物药业股份有限公司 关于拟计提资产减值准备的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次拟计提资产减值准备情况 二、本次拟计提资产减值准备的具体说明 1、信用减值损失 根据《企业会计准则第22号－金融工具确认和计量》相关规定，公司以预 期信用损失为基础，对应收票据、应收账款、其他应收款等进行减值测试并确 认减值损失。经初步测试，本次拟计提信用减值损失65.00万元。 2、资产减值损失 根据《企业会计准则第1号－存货》和公司相关会计政策，资产负债表日， 存货应当按照成本与可变现净值孰低计量。当存货成本高于其可变现净值的， 应当计提存货跌价准备。计提存货跌价准备后，如果以前减记存货价值的影响 因素已经消失，导致存货的可变现净值高于其账面价值的，在原已计提的存货 跌价准备金额内予以转回，转回的金额计入当期损益。经初步测算，本报告期 公司拟计提资产减值损失850.00万元，为公司存货跌价损失。 三、本次拟计提资产减值准备对公司的影 ...